← All trials
NCT06452277
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 28, 2024
- Primary completion
- Jun 2, 2026
- Completion date
- May 15, 2028
- First posted
- Jun 11, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 278
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BayerLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.